Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to $61,000.

  • Seres Therapeutics' Cash from Financing Activities rose 100.06% to $61,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.9 million, marking a year-over-year decrease of 28.08%. This contributed to the annual value of -$90.4 million for FY2024, which is 226.03% down from last year.
  • Seres Therapeutics' Cash from Financing Activities amounted to $61,000 in Q3 2025, which was down 94.83% from $1.2 million recorded in Q1 2025.
  • Seres Therapeutics' Cash from Financing Activities' 5-year high stood at $98.0 million during Q3 2022, with a 5-year trough of -$110.9 million in Q3 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.7 million (2024), whereas its average is -$1.9 million.
  • In the last 5 years, Seres Therapeutics' Cash from Financing Activities soared by 44,651.54% in 2023 and then slumped by 7,783.37% in 2024.
  • Over the past 5 years, Seres Therapeutics' Cash from Financing Activities (Quarterly) stood at -$780,000 in 2021, then soared by 689.36% to $4.6 million in 2022, then soared by 39.85% to $6.4 million in 2023, then tumbled by 72.98% to $1.7 million in 2024, then skyrocketed by 100.06% to $61,000 in 2025.
  • Its last three reported values are $61,000 in Q3 2025, $1.2 million for Q1 2025, and $1.7 million during Q4 2024.